Roles of rifampicin in drug-drug interactions: Underlying molecular mechanisms involving the nuclear pregnane X receptor

Annals of Clinical Microbiology and Antimicrobials

Volumn 5, Issue , 2006, Pages

  Chen, Jiezhong ^a   Raymond, Kenneth ^a  

^a LA TROBE UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; AMPRENAVIR; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDIABETIC AGENT; ANTIHISTAMINIC AGENT; BUSPIRONE; CARDIOVASCULAR AGENT; CODEINE; CONTRACEPTIVE AGENT; CYCLOSPORIN; CYTOCHROME P450; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DAPSONE; DIGOXIN; FELODIPINE; GLUCURONOSYLTRANSFERASE; GLYCOPROTEIN P; HEXOBARBITAL; PREDNISOLONE; PREGNANE X RECEPTOR; PROPAFENONE; QUINIDINE; RIFAMPICIN; ROPIVACAINE; TOLBUTAMIDE; TRAMAZOLINE; UNINDEXED DRUG; VERAPAMIL; CELL RECEPTOR; STEROID RECEPTOR; TUBERCULOSTATIC AGENT;

AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; GASTROINTESTINAL TRACT; GENE ACTIVATION; HUMAN; LIVER; MOLECULAR MECHANICS; NONHUMAN; PROTEIN FUNCTION; REVIEW; TISSUE DISTRIBUTION; TREATMENT FAILURE; TUBERCULOSIS; CELL NUCLEUS; DRUG EFFECT; DRUG INTERACTION; METABOLISM; PHYSIOLOGY;

ANTIBIOTICS, ANTITUBERCULAR; CELL NUCLEUS; DRUG INTERACTIONS; GLUCURONOSYLTRANSFERASE; HUMANS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID; RIFAMPIN; TUBERCULOSIS;

EID: 33644843888     PISSN: 14760711     EISSN: 14760711     Source Type: Journal    
DOI: 10.1186/1476-0711-5-3     Document Type: Review

References (133)

1. Dlodlo RA, Fujiwara Pl, Enarson DA: Should tuberculosis treatment and control be addressed differently in HIV-infected and -uninfected individuals? Eur Respir J 2005, 25:751-7.
2. Nies AS: Principles of the therapeutics. In Goodman & Gilman's The Pharmacological Basis of Therapeutics 10th edition. Edited by: Hardman JG, Limbird LE, Molinoff PB. New York: McGraw-Hill Inc; 2001:45-66.
3. le Grand A, Hogerzeil HV, Haaijer-Ruskamp FM: Intervention research in rational use of drugs: a review. Health Policy Plan 1999, 14:89-102.
4. Davies PD, Yew WW: Recent developments in the treatment of tuberculosis. Expert Opin Investig Drugs 2003, 12:1297-312
5. Mitchison DA: The diagnosis and therapy of tuberculosis during the past 100 years. Am J Respir Crit Care Med 2005, 171:699-706.
6. Guernsey BG, Alexander MR: Tuberculosis: review of treatment failure, relapse and drug resistance. Am J Hosp Pharm 1978, 35:690-8.
7. Neralla S, Glassroth J: Mycobacterium tuberculosis: the treatment of active disease. Semin Respir Infect 2003, 18:392-306.
8. Benedetti SM, Efthymiopoulos C, Sassella. D, et al.: Autoinduction of rifabutin metabolism in man. Xenobiotica 1990, 20:1113-9.
9. Benedetti SM, Dostert P: Induction and autoinduction properties of rifamycin derivatives: a review of animal and human studies. Environ Health Perspect 1994, 102: 101-5.
10. Loos U, Musch E, Jensen JC, et al: Pharmacokinetics of oral and intravenous rifampicin during chronic administration. Klin Wochenschr 1985, 63:1205-11.
11. Jordan MK, Polis MA, Kelly G, et al.: Effects of fluconazole and clarithromycin on rifabutin and 25-O-desacetylrifabutin pharmacokinetics. Antimicrob Agents Chemother 2000, 44:2170-2.
12. Karan RS, Bhargava VK, Garg SK: Effect of trikatu, an Ayurvedic prescription, on the pharmacokinetic profile of rifampicin in rabbits. J Ethnopharmacology 1999, 64:259-264.
13. Niemi M, Backman JT, Fromm MF, et al.: Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003, 42:819-50.
14. Baciewicz AM, Self TH: Rifampin drug interactions. Arch Intern Med 1984, 144:1667-71.
15. Venkatesan K: Pharmacokinetic drug interactions with rifampicin. Clin Pharmacokinet 1992, 22:47-65.
16. Borcherding SM. Baciewicz AM, Self TH: Update on rifampin drug interactions. II. Arch Intern Med 1992, 152:711-6.
17. Strayhorn VA, Baciewicz AM, Self TH: Update on rifampin drug interactions, III. Arch Intern Med 1997, 157:2453-8.
18. Burman WJ, Gallicano K, Peloquin C: Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet 2001, 40:327-41.
19. Finch CK, Chrisman CR, Baciewicz AM: Rifampin and rifabutin drug interactions: an update. Arch Intern Med 2002, 162:985-92.
20. Yew WW: Clinically significant interactions with drugs used in the treatment of tuberculosis. Drug Saf 2002, 25:111-33.
21. Bertilsson G, Heidrich J, Svensson K: Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci U S A 1998, 95:12208-13.
22. Blumberg B, Sabbagh WJr, Juguilon H: SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev 1998, 12:3195-205.
23. Kliewer SA, Moore JT, Wade L: An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 1998, 92:73-82.
24. Lehmann JM, McKee DD, Watson MA: The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 1998, 102:1016-23.
25. Goodwin B, Hodgson E, Liddle C: The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol Pharmacol 1999, 56:1329-39.
26. Watkins RE, Wisely GB, Moore LB: The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science 2001, 292:2329-33.
27. Kliewer SA, Willson TM: Regulation of xenobiotic and bile acid metabolism by the nuclear pregnane X receptor. J Lipid Res 2002, 43:359-64.
28. Tirona RG, Lee W, Leake BF. The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat Med 2003, 9:220-4.
29. Cummins CL, Salphati L, Reid MJ: In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: studies using the rat single-pass intestinal perfusion model. J Pharmacol Exp Ther 2003, 305:306-14.
30. Self TH, Mann RB: Interaction of rifampin and warfarin. Chest 1975, 67:490-1.
31. Zilly W, Breimer DD, Richter E: Stimulation of drug metabolism by rifampicin in patients with cirrhosis or cholestasis measured by increased hexobarbital and tolbutamide clearance. Eur J Clin Pharmacol 1977, 11:287-93.
32. Back D, Breckenridge AM, Crawford FE: The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women. Contraception 1980, 21:135-43.
33. Herman RJ, Nakamura K, Wilkinson GR: Induction of propranolol metabolism by rifampicin. Br J Clin Pharmacol 1983, 16:565-9.
34. McAllister WA, Thompson PJ, Al-Habet SM: Rifampicin reduces effectiveness and bioavailability of prednisolone. Br Med J (Clin Res Ed) 1983, 286:923-5.
35. Schoene B, Fleischmann RA, Remmer H: Determination of drug metabolizing enzymes in needle biopsies of human liver. Eur J Clin Pharmacol 1972, 4:65-73.
36. Nelson DR, Kamataki T, Waxman DJ: The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol 1993, 12:1-51.
37. Nelson DR, Koymans L, Kamataki T: P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996, 6:1-42.
38. Reimers D, Jezek A: The simultaneous use of rifampicin and, other antitubercular agents with oral contraceptives. Prax Pneumol 1971, 25:255-62.
39. Bolt HM, Bolt M, Kappus H: Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethyloestradiol in man. Acta Endocrinol 1977, 85:189-197.
40. Bolt HM: Rifampicin, a keystone inducer of drug metabolism: from Herbert Remmer's pioneering ideas to modern concepts. Drug Metabolism Reviews 2004, 36:497-509.
41. Guengerich FP: Metabolism of 17 alpha-ethynylestradiol in humans. Life Sci 1990, 47:1981-1988.
42. Badawi AF, Cavalieri EL, Rogan EG: Role of human cytochrome P450 1A1, 1A2, 1B1, and 3A4 in the 2-, 4-, and 16alpha-hydroxylation of 17beta-estradiol. Metabolism 2001, 50:1001-1003.
43. Lee AJ, Cai MX, Thomas PE: Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology 2003, 144:3382-3398.
44. Xie W, Barwick JL, Downes M: Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature 2000, 406:435-9.
45. Maglich JM, Stoltz CM, Goodwin B: Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol Pharmacol 2002,62:638-46.
46. Waxman DJ: P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. Arch Biochem Biophys 1999, 369:11-23.
47. Song X, Xie M, Zhang H: The pregnane X receptor binds to response elements in a genomic context-dependent manner, and PXR activator rifampicin selectively alters the binding among target genes. Drug Metab Dispos 2004,32:35-42.
48. Rae JM, Johnson MD, Lippman ME: Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes. J Pharmacol Exp Ther 2001, 299:849-57.
49. Goodwin B, Hodgson E, D'Costa DJ: Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor. Mol Pharmacol 2002, 62:359-65.
50. Katoh M, Matsui T, Nakajima M: I n vivo induction of human cytochrome P450 enzymes expressed in chimeric mice with humanized liver. Drug Metab Dispos 2005, 35:863-75.
51. Waxman DJ, Azaroff L: Phenobarbital induction of cytochrome P-450 gene expression. Biochem J 1992, 281:577-92.
52. Nebert DW, Russell DW: Clinical importance of the cytochromes P450. Lancet 2002, 360:1155-62.
53. Werck-Reichhart D, Feyereisen R: Cytochromes P450: a success story. Genome Biol 2000, 1:1-9.
54. Tucker GT: Advances in understanding drug metabolism and its contribution to variability in patient response. Ther Drug Monit 2000, 22:110-3.
55. Li AP, Kaminski DL, Rasmussen A: Substrates of human hepatic cytochrome P450 3A4. Taxicology 1995, 104:1-8.
56. Waxman DJ, Lapenson DP, Aoyama T: Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Arch Biochem Biophys 1991, 290:160-6.
57. Yano JK, Wester MR, Schoch GA: The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05 ' resolution. J Biol Chem 2004, 279:38091-4.
58. Denison MS, Whitlock JPJr. Xenobiotic-inducible transcription of cytochrome P450 genes. J Biol Chem 1995, 270:18175-8.
59. Meyer UA: Overview of enzymes of drug metabolism. J Pharmacokinet Biopharm 1996, 24:449-59.
60. Dogra SC, Whitelaw ML, May BK: Transcriptional activation of cytochrome P450 genes by different classes of chemical inducers. Clin Exp Pharmacol Physiol 1998, 25:1-9.
61. Hesse LM, Sakai Y, Vishnuvardhan D: Effect of bupropion on CYP2B6 and CYP3A4 catalytic activity, immunoreactive protein and mRNA levels in primary human hepatocytes: comparison with rifampicin. J Pharm Pharmacol 2003, 55:1229-39.
62. Shimada T, Yamazaki H, Mimura M: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994, 270:414-23.
63. Liddle C, Goodwin BJ, George J: Separate and interactive regulation of cytochrome P450 3A4 by triiodothyronine, dexamethasone, and growth hormone in cultured hepatocytes. J Clin Endocrinol Metab 1998, 83:2411-6.
64. Gashaw I, Kirchheiner J, Goldammer M: Cytochrome P4503A4 messenger ribonucleic acid induction by rifampin in human peripheral blood mononuclear cells: correlation with alprazolam pharmacokinetics. Clin Pharmacol Ther 2003, 74:448-57.
65. Matsuda H, Kinoshita K, Sumida A: Taurine modulates induction of cytochrome P450 3A4 mRNA by rifampicin in the HepG2 cell line. Biochim Biophys Acta 2002, 1593:93-8.
66. Glaeser H, Drescher S, Eichelbaum M: Influence of rifampicin on the expression and function of human intestinal cytochrome P450 enzymes. Br J Clin Pharmacol 2005, 59:199-206.
67. Barwick JL, Quattrochi LC, Mills AS: Trans-species gene transfer for analysis of glucocorticoid-inducible transcriptional activation of transiently expressed human CYP3A4 and rabbit CYP3A6 in primary cultures of adult rat and rabbit hepatocytes. Mol Pharmacol 1996, 50:10-16.
68. Trapnell CB, Narang PK, Li R: Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients. Ann Intern Med 1996, 124:573-6.
69. Relling MV, Nemec J, Schuetz EG: O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mel Pharmacol 1994, 45:352-8.
70. Watkins PB, Murray SA, Winkelman LG: Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients. J Clin Invest 1989, 83:688-97.
71. Kolars JC, Schmiedlin-Ren P, Schuetz JD: Identification of rifampin-inducible P450111A4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992, 90:1871-8.
72. Chen Y, Ferguson SS, Negishi M: Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. J Pharmacol Exp Ther 2004, 308:495-501.
73. Faucette SR, Wang H, Hamilton GA: Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. Drug Metab Dispos 2004, 32:348-58.
74. Wang H, Faucette S, Sueyoshi: A novel distal enhancer module regulated by pregnane X receptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression. J Biol Chem 2003, 278:14146-52.
75. Jemnitz K, Lengyel G, Vereczkey L: In vitro induction of bilirubin conjugation in primary rat hepatocyte culture. Biochem Biophys Res Commun 2002, 291:29-33.
76. Soars MG, Petullo DM, Eckstein JA: An assessment of udp-glucuronosyltransferase induction using primary human hepatocytes. Drug Metab Dispos 2004, 32:140-8.
77. Tukey RH, Strassburg CP: Genetic multiplicity of the human UDP-glucuronosyltransferases and regulation in the gastrointestinal tract. Mol Pharmacol 2001, 59:405-14.
78. Sugatani J. Kojima H, Ueda A: The phenobarbital response enhancer module in the human bilirubin UDP-glucuronosyltransferase UGT1A1 gene and regulation by the nuclear receptor CAR. Hepatology 2001, 33:1232-8.
79. Xie W, Yeuh MF, Radominska-Pandya A: Control of steroid, heme, and carcinogen metabolism by nuclear pregnane X receptor and constitutive androstane receptor. Proc Natl Acad Sci U S A 2003, 100:4150-5.
80. Yueh MF, Huang YH, Hiller A: Involvement of the xenobiotic response element (XRE) in Ah receptor-mediated induction of human UDP-glucuronosyltransferase lAl. J Biol Chem 2003, 278:15001-16.
81. Sugatani J, Yamakawa K, Tonda E: The induction of human UDP-glucuronosyltransferase lAl mediated through a distal enhancer module by flavonoids and xenobiotics. Biochem Pharmacol 2004, 67:989-1000.
82. Juliano RL, Ling VA: Surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976, 455:152-62.
83. Mizuno N, Niwa T, Yotsumoto Y: Impact of drug transporter studies on drug discovery and development. Pharmacol Rev 2003, 55.425-61.
84. Tanigawara Y: Role of P-glycoprotein in drug disposition. Ther Drug Monit 2000, 22:137-40.
85. von Richter O, Burk O, Fromm MF: Cytochrome P4503A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther 2004, 75:172-83.
86. Schuetz EG, Beck WT, Schuetz JD: Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately upregulate these proteins in human colon carcinoma cells. Mol Pharmacol 1996, 49:311-8.
87. Johnson BM, Chen W, Borchardt RT: A kinetic evaluation of the absorption, efflux, and metabolism of verapamil in the autoperfused rat jejunum. J Pharmacol Exp Ther 2003, 305:151-8.
88. Greiner B, Eichelbaum M, Fritz P: The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999, 104:147-53.
89. Dresser GK, Bailey DG: The effects of fruit juices on drug disposition: a new model for drug interactions. Eur J Clin Invest 2003, 2:10-16.
90. Asghar A, Gorski JC, Haehner-Daniels B: Induction of multidrug resistance-I and cytochrome P450 mRNAs in human mononuclear cells by rifampin. Drug Metab Dispos 2002, 30:20-6.
91. Westphal K, Weinbrenner A, Zschiesche M: Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin Pharmacol Ther 2000, 68:345-55.
92. Giessmann T, Modess C, Hecker U: CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects. Clin Pharmacol Ther 2004, 75:213-22.
93. Geick A, Eichelbaum M, Burk O: Nuclear receptor response elements mediate induction of intestinal MDRI by rifampin. J Biol Chem 2001, 276:14581-7.
94. Zhao JY, Ikeguchi M, Eckersberg T: Modulation of multidrug resistance gene expression by dexamethasone in cultured hepatoma cells. Endocrinology 1993, 133:521-8.
95. Lin JH, Chiba M, Chen IW: Effect of dexamethasone on the intestinal first-pass metabolism of indinavir in rats: evidence of cytochrome P-4503A [correction of P-450 A] and p-glycoprotein induction. Drug Metab Dispos 1999, 27:1187-93.
96. Chen WS, Manova K, Weinstei DC: Disruption of the HNF-4 gene, expressed in visceral endoderm, leads to cell death in embryonic ectoderm and impaired gastrulation of mouse embryos. Genes Dev 1994, 8:2466-77.
97. Kamiya A, Inoue Y, Gonzalez FJ: Role of the hepatocyte nuclear factor 4alpha in control of the pregnane X receptor during fetal liver development. Hepatology 2003, 37:1375-84.
98. Jover R, Bort R, Gomez-Lechon M: Cytochrome P450 regulation by hepatocyte nuclear factor 4 in human hepatocytes: a study using adenovirus-mediated antisense targeting. Hepatology 2001, 33:668-75.
99. El-Sankary W, Bombail V, Gibson GG: Glucocorticoid-mediated induction of CYP3A4 is decreased by disruption of a protein: DNA interaction distinct from the pregnane X receptor response element. Drug Metab Dispos 2002, 30:1029-34.
100. Thummel KE, Brimer C, Yasuda K: Transcriptional control of intestinal cytochrome P-4503A by 1alpha,25-dihydroxy vitamin D3. Mol Pharmacol 2001, 60:1399-406.
101. Schmiedlin-Ren P, Thummel KE, Fisher JM: Induction of CYP3A4 by 1 alpha, 25-dihydroxyvitamin D3 is human cell line-specific and is unlikely to involve pregnane X receptor. Drug Metab Dispos 2001, 29:1446-53.
102. Elizondo G, Medina-Diaz IM: Induction of CYP3A4 by 1 alpha, 25-dyhydroxyvitamin D3 in HepG2 cells. Life Sci 2003, 73:141-9.
103. Edwards DJ, Fitzsimmons ME, Schuetz EG: 6′,7′-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein. Clin Pharmacol Ther 1999, 65:237-44.
104. Christensen H, Asberg A, Holmboe AB: Coadministration of grapefruit juice increases systemic exposure of diltiazem in healthy volunteers. Eur J Clin Pharmacol 2002, 58:515-20.
105. Kim YH, Yoon YR, Kim YW: Effects of rifampin on cyclosporine disposition in kidney recipients with tuberculosis. Transplant Proc 1998, 30:3570-2.
106. Zelunka EJ: Intravenous cyclosporine-rifampin interaction in a pediatric bone marrow transplant recipient. Pharmacotherapy 2002, 22:387-90.
107. Combalbert J, Fabre I, Fabre G: Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450111A gene subfamily. Drug Metab Dispos 1989, 17:197-207.
108. Mousa O, Brater DC, Sunblad KJ: The interaction of diltiazem with simvastatin. Clin Pharmacol Ther 2000,67:267-74.
109. Kyrklund C, Backman JT, Kivisto KT: Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 2000, 68:592-7.
110. Park JY, Kim KA, Kang MH: Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. Clin Pharmacol Ther 2004, 75:157-62.
111. Baldwin SJ, Clarke SE, Chenery RJ: Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol 1999, 48:424-32.
112. Kaminsky LS, Zhang ZY: Human P450 metabolism of warfarin. Pharmacol Ther 1997, 73:67-74.
113. Lee CR, Thrasher KA: Difficulties in anticoagulation management during coadministration of warfarin and rifampin. Pharmacotherapy 2001, 21:1240-6.
114. Hesse LM, Venkatakrishnan K, Court MH: CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 2000, 28:1176-83.
115. Hesse LM, He P, Krishnaswamy S: Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics 2004, 14:225-238.
116. Hinderling PH, Hartmann D: Pharmacokinetics of digoxin and main metabolites/derivatives in healthy humans. Ther Drug Monit 1991, 13:381-401.
117. Lacarelle B, Rahmani R, de Sousa G: Metabolism of digoxin, digoxigenin digitoxosides and digoxigenin in human hepatocytes and liver microsomes. Fundam Clin Pharmacol 1991, 5:567-82.
118. Jokinen MJ, Olkkola KT, Ahonen J: Effect of rifampin and tobacco smoking on the pharmacokinetics of ropivacaine. Clin Pharmacol 2001, 70:334-50.
119. Labbe I, Turgeon J: Clinical pharmacokinetics of mexiletine. Clin Pharmacokinet 1999, 37:361-84.
120. Dilger K, Hofmann U, Klotz U: Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone. Clin Pharmacol Ther 2000, 67:512-20.
121. Bolton AE, Peng B, Hubert M: Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, ST1571) in healthy subjects. Cancer Chemother Pharmacol 2004, 53:102-6.
122. Sahi J, Stern RH, Milad MA: Effects of avasimibe on cytochrome P450 2C9 expression in vitro and in vivo. Drug Metab Dispos 2004, 32:1370-6.
123. Hamman MA, Bruce MA: Haehner-Daniels BD. The effect of rifampin administration on the disposition of fexofenadine. Clin Pharmacol Ther 2001, 69:114-21.
124. Apseloff G, Foulds G, LaBoy-Goral L: Comparison of azithromycin and clarithromycin in their interaction with rifabutin in healthy volunteers. J Clin Pharmacol 1998, 38.830-5.
125. Self T, Corley CR, Nabhan S: Case report: interaction of rifampin and nortriptyline. Am J Med Sci 1996, 311:80-1.
126. Abajo FJ: Phenytoin interaction with rifampicin. BMJ 1988, 297:1048.
127. Park JY, Kim KA, Kang MH: Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. Clin Pharmacol Ther 2004, 75:157-62.
128. Prince MI, Burt AD, Jones DE: Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut 20O2 50:436-9.
129. Cancado EL, Leitao RM, Carrilho FJ: Unexpected clinical remission of cholestasis after rifampicin therapy in patients with normal or slightly increased levels of gamma-glutamyl transpeptidase. Am J Gastroenterol 1998, 93:1510-7.
130. Sharma SK: Antituberculosis drugs and hepatotoxicity. Infection, genetics and evolution 2004, 4:167-170.
131. Black M, Mitchell JR, Zimmerman HJ: Isoniazid-associated hepatitis in 114 patients. Gastroenterology 1975, 69:289-302.
132. Bertolami MC: [Mechanisms of hepatotoxicity]. Arq Bras Cardiol 2005, 85(Suppl 5):25-27.
133. Sodhi CP, Rana SV, Mehta SK, Vaiphei K. Attari S, Mehta S: Study of oxidative-stress in isoniazid-rifampicin induced hepatic injury in young rats. Drug Chem Toxicol 1997, 20:255-269.